Clinical and [99mTc]TRODAT-1/[123I]IBZM SPECT imaging findings in dopa-responsive dystonia

Eur Neurol. 2004;51(1):26-9. doi: 10.1159/000074914. Epub 2003 Nov 18.

Abstract

We report the clinical and dopamine transporter/D2 receptor single-photon emission computed tomographic (SPECT) imaging findings in a 39-year-old woman with a 24-year history of dopa-responsive dystonia (DRD). The SPECT imaging of the dopamine transporter with [(99m)Tc]TRODAT-1 is helpful in differentiating DRD from early-onset idiopathic parkinsonism. In the later clinical course, the [(123)I]IBZM SPECT is also helpful in differentiating these two conditions. The patient showed a dramatic and sustained response to levodopa, and needed a smaller dose of levodopa for symptom control in the later course.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Benzamides*
  • Brain / diagnostic imaging
  • Brain / metabolism*
  • Contrast Media
  • Diagnosis, Differential
  • Dopamine Agents / therapeutic use
  • Dopamine Plasma Membrane Transport Proteins
  • Dystonia / diagnostic imaging
  • Dystonia / drug therapy
  • Dystonia / metabolism*
  • Female
  • Humans
  • Levodopa / therapeutic use*
  • Membrane Glycoproteins*
  • Membrane Transport Proteins / metabolism*
  • Nerve Tissue Proteins*
  • Organotechnetium Compounds*
  • Parkinsonian Disorders / diagnosis
  • Pyrrolidines*
  • Radiopharmaceuticals
  • Receptors, Dopamine D2 / metabolism
  • Tomography, Emission-Computed, Single-Photon* / methods
  • Tropanes*

Substances

  • Benzamides
  • Contrast Media
  • Dopamine Agents
  • Dopamine Plasma Membrane Transport Proteins
  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Nerve Tissue Proteins
  • Organotechnetium Compounds
  • Pyrrolidines
  • Radiopharmaceuticals
  • Receptors, Dopamine D2
  • Tropanes
  • technetium Tc 99m TRODAT-1
  • Levodopa
  • 3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide